The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells

Leukemia. 2019 Jan;33(1):262-266. doi: 10.1038/s41375-018-0201-2. Epub 2018 Jul 15.

Authors

Zhaodong Li¹, Shuning He¹, A Thomas Look^{2

3}

Affiliations

¹ Department of Paediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA.
² Department of Paediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA. [email protected].
³ Division of Haematology/Oncology, Boston Children's Hospital, Boston, MA, 02215, USA. [email protected].

No abstract available

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Animals
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bridged Bicyclo Compounds, Heterocyclic / administration & dosage
Drug Synergism*
Embryo, Nonmammalian / drug effects
Embryo, Nonmammalian / metabolism
Embryo, Nonmammalian / pathology*
Humans
Myeloid Cell Leukemia Sequence 1 Protein / antagonists & inhibitors*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology*
Pyrimidines / administration & dosage
Sulfonamides / administration & dosage
T-Lymphocytes / drug effects
T-Lymphocytes / metabolism
T-Lymphocytes / pathology*
Thiophenes / administration & dosage
Tumor Cells, Cultured
Zebrafish

Substances

Bridged Bicyclo Compounds, Heterocyclic
MCL1 protein, human
Myeloid Cell Leukemia Sequence 1 Protein
Pyrimidines
S63845
Sulfonamides
Thiophenes
venetoclax

Grants and funding